Health care giant Johnson & Johnson reported Tuesday a profit for the second quarter that increased four percent from last year, despite negative currency effects, reflecting strength of its rheumatoid arthritis drugs Remicade and Simponi in the U.S. Adjusted earnings per share and quarterly revenues topped analysts’ expectation. The company also raised earnings forecast for the full-year 2015.